A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...